{"nct_id":"NCT06797635","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","status_verified_date":"2025-10","start_date":"2025-03-20","start_date_type":"ACTUAL","primary_completion_date":"2029-12-31","primary_completion_date_type":"ESTIMATED","completion_date":"2034-12-31","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}